Correlation between HIF1A-AS2 expression and clinicopathological characteristics of renal cell cancer patients (clear cell renal cell carcinomas)
| Characteristics | Total | Expression of HIF1A-AS2 | P | |
|---|---|---|---|---|
| Higher, n = 58 | Lower, n = 25 | |||
| Gender | 0.326 | |||
| Male | 51 | 38 (74.5%) | 13 (25.5%) | |
| Female | 32 | 20 (62.5%) | 12 (37.5%) | |
| Age (years) | 0.456 | |||
| ≤ 50 | 28 | 18 (64.3%) | 10 (35.7%) | |
| > 50 | 55 | 40 (72.7%) | 15 (27.3%) | |
| Tumor size (cm) | 0.027* | |||
| ≤ 7 | 31 | 17 (54.8%) | 14 (45.2%) | |
| > 7 | 52 | 41 (78.8%) | 11 (21.2%) | |
| Differentiation | 0.007** | |||
| Moderate/poor | 49 | 40 (81.6%) | 9 (18.4%) | |
| Well | 34 | 18 (52.9%) | 16 (47.1%) | |
| TNM stage | 0.007** | |||
| T0-1 | 31 | 16 (51.6%) | 15 (48.4%) | |
| T2-4 | 52 | 42 (80.8%) | 10 (19.2%) | |
| Lymph node metastasis | 0.548 | |||
| N0 | 67 | 48 (71.6%) | 19 (28.4%) | |
| N1 or above | 16 | 10 (62.50%) | 6 (37.5%) | |
*P < 0.05; **P < 0.01. Tumor node metastasis according to staging TNM of the American Joint Committee on Cancer in 2010.